The REDUCE-IT trial showed a highly significant 25% reduction in the primary composite ASCVD endpoint – a reduction that was greater than would be anticipated by the achieved 20% lowering of triglycerides alone, suggesting other non-lipid mechanisms for benefit.
← all excerpts
Fellow's voice: Hypertriglyceridemia: Understanding the current guideline.
1
—
—